BRIACELL THERAPEUTICS CORP. Depreciation
BRIACELL THERAPEUTICS CORP. (BCTX) reported Depreciation of $74.87 thousand for the 9-month period ending 2026-04-30, per its 10-Q filed 2026-06-09.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-06-09
- BRIACELL THERAPEUTICS CORP. depreciation for the quarter ending 2026-04-30 was $29.19K, a 27.82% increase year-over-year.
- BRIACELL THERAPEUTICS CORP. depreciation for the quarter ending 2026-01-31 was $22.84K, a 0.00% change year-over-year.
- BRIACELL THERAPEUTICS CORP. depreciation for the quarter ending 2025-10-31 was $22.84K, a 0.00% change year-over-year.
- BRIACELL THERAPEUTICS CORP. depreciation for the quarter ending 2025-07-31 was $22.84K.
- BRIACELL THERAPEUTICS CORP. depreciation for fiscal 2025 was $91.36K, a 33.12% increase from fiscal 2024.
- BRIACELL THERAPEUTICS CORP. depreciation for fiscal 2024 was $68.63K.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|
| 2026-04-30 | $29.19K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-06-09 | $52.03K derived: sum of 2 quarters · filed 2026-06-09 | $74.87K 10-Q · filed 2026-06-09 | $97.71K derived: sum of 4 quarters · filed 2026-06-09 |
| 2026-01-31 | $22.84K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-03-10 | $45.68K 10-Q · filed 2026-03-10 | $68.52K derived: sum of 3 quarters · filed 2026-03-10 | $91.36K derived: sum of 4 quarters · filed 2026-06-09 |
| 2025-10-31 | $22.84K 10-Q · filed 2025-12-11 | $45.68K derived: sum of 2 quarters · filed 2025-12-11 | $68.52K derived: sum of 3 quarters · filed 2026-06-09 | $91.36K derived: sum of 4 quarters · filed 2026-06-09 |
| 2025-07-31 | $22.84K derived: 10-K 12 month − 10-Q 9 month · filed 2025-10-16 | $45.68K derived: sum of 2 quarters · filed 2026-06-09 | $68.52K derived: sum of 3 quarters · filed 2026-06-09 | $91.36K 10-K · filed 2025-10-16 |
| 2025-04-30 | $22.84K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-06-09 | $45.68K derived: sum of 2 quarters · filed 2026-06-09 | $68.52K 10-Q · filed 2026-06-09 | |
| 2025-01-31 | $22.84K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-03-10 | $45.68K 10-Q · filed 2026-03-10 | ||
| 2024-10-31 | $22.84K 10-Q · filed 2025-12-11 | |||
| 2024-07-31 | $68.63K 10-K · filed 2025-10-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |